|Bid||35.03 x 900|
|Ask||35.07 x 1200|
|Day's Range||33.62 - 35.26|
|52 Week Range||17.60 - 68.90|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.00|
Alan Auerbach has been the CEO of Puma Biotechnology, Inc. (NASDAQ:PBYI) since 2011. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth that the bu...
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on April 3, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 45,625 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or HER2 mutation. The cohorts that have been expanded are (i) HER2 mutant patients with metastatic salivary gland cancer and (ii) patients with EGFR exon 18 mutation-positive lung cancer. The Phase II SUMMIT basket trial is an open-label, multi-center, multi-histology, international study to evaluate the safety and efficacy of neratinib administered daily to patients who have solid tumors with activating EGFR, HER2 or HER4 mutations.
Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.
Puma Biotechnology, Inc. and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX® within Europe and part of Africa.
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research Annual Meeting 2019.
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Puma Biotechnology Inc NASDAQ/NGS:PBYIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NegativeShort interest is moderately high for PBYI with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 15. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PBYI are favorable, with net inflows of $3.71 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Oral Plenary Presentation Receives SGO Presidential Award
LOS ANGELES-- -- Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Treatment with neratinib in the approved indication resulted in a 34% reduction in the risk of invasive disease recurrence or death versus placebo after patients completed one year of therapy ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:00 a.m.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.